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Carbonic anhydraseFerrier sulfamidoglycosylation of glycals catalyzed by nitrosonium tetrafluoroborate allowed the prepa-
ration of hydroxysulfamide glycosides in good yields with a good a stereoselectivity. A variety of mono-
saccharide derivatives was synthesized using this new methodology leading to selective and powerful
glycoinhibitors of the tumor associated carbonic anhydrases (CA, EC 4.2.1.1) isoforms CA IX and CA XII.
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The development of carbonic anhydrases (CA, EC 4.2.1.1) gly-
coinhibitors is currently a dynamic field which constitutes one of
the most successful approaches to find new active and selective
inhibitors with potent biomedical applications.1 Carbohydrate
based CA inhibitors were already found to be effective as antiglau-
coma or anti-epileptic agents.1 Some recent work from our group
also demonstrated the validity of this approach in the field of can-
cer as we were able to demonstrate that carbonic anhydrase inhib-
itors belonging to a glycosylcoumarin series were strong, selective
CA IX inhibitors and were able to reduce the growth of primary
tumors and metastases in a human and mouse model of ortho-
topic, CA IX-positive breast cancer2 and also to deplete cancer stem
cells within these tumors.3 In our ongoing researches in the devel-
opment of new and original glycoinhibitors incorporating the
hydroxysulfamide scaffold as zinc binding function,4 we were
interested to find a synthetic methodology allowing the access to
2,3-unsaturated glycosides 5 starting from a peracetylated glycals
platform (Scheme 1).
Based on previous works reported by Colinas and Bravo5
describing the Ferrier sulfonamidoglycosylation of glycals, we
sought to extend this methodology to sulfamides using thenon-metallic catalyst nitrosyl tetrafluoroborate. Indeed, NOBF4
was recently demonstrated by Misra and Coll.6 to be efficient for
the stereoselective glycosylation reaction as well as for the prepa-
ration of 2,3-unsaturated glycosides and 2-deoxyglycosides. In this
paper, we report our findings on this reaction and also the inhibi-
tory activity of the obtained N-glycosyl-N-hydroxysulfamides
against four relevant CA isoforms.
2. Results and discussion
We first focused our attention to the conditions for the Ferrier
sulfamidoglycosylation of the tri-O-acetyl-D-glucal with N-(O-
tert-butyldiphenylsilyl)hydroxysulfamide 1, prepared initially
from the commercial hydroxylamine hydrochloride, following abed4 and
Table 1
Optimized results for the Ferrier sulfamidoglycosylation and deprotection steps
Glycals 1 Step 1a Steps 2+3b
Yield %/a/b ratio/reaction time Yield %/a/b ratio
2a D: 68/60:40/45 min
MW: 70/60:40/20 min
85/77:23
2b D: 70/75:25/45 min
MW: 70/75:25/20 min
85/77:23
2c D: 88/60:40/45 min
MW: 90/60:40/20 min
85/77:23
2d D: 86/60:40/45 min
MW: 90/60:40/20 min
85/77:23
2e D: 88/84:16/45 min
MW: 90/84:16/20 min
85/77:23
a Reaction conditions: glycal (1) 1 equiv N-(O-tert-butyldiphenylsilyl)hydrox-
ysulfamide 1.1 equiv, NOBF4 0.05 equiv, CH2Cl2.
b HF-pyridine 70%, CH3CN, RT, then NH3/MeOH.
NH2-OH, HCl H2N
S
O O
N
H
O
TBDPS
1) TBDPSCl, NEt3, 0°C, CH2Cl2
2) CSI, tBuOH, 0°C, CH2Cl2
1 (78%)
3) 10% TFA, CH2Cl2
Scheme 2. Synthesis of N-(O-tert-butyldiphenylsilyl)hydroxysulfamide 1.
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was first O-protected with the tert-butyldiphenylsilyl protecting
group, and then sulfamoylated with tert-butoxysulfamoyl chloride,
prepared ab initio by reacting chlorosulfonyl isocyanate with tert-
butanol. Final Boc deprotection with 10% TFA solution in methy-
lene chloride allowed formation of compound 1 in an overall yield
of 78%.7
First attempts of sulfamidoglycosylation of glycal 2was realized
using the classical Lewis acid BF3.Et2O, widely used as catalyst in
Ferrier rearrangement of glycals and described in 2007 by Colinas
research group as a good catalyst of the Ferrier sulfonamidoglyco-
sylation of D-glycals.5 Unfortunately, low reaction yields (around
20%), obtained with this catalyst, led us to use NOBF4, recently
reported as mild, efficient and inexpensive catalyst for the Ferrier
rearrangement reaction.6
In order to improve in term of efficiency, selectivity, time and
yield of reaction we investigated the reaction in the presence of a
variable amount of NOBF4, at different temperatures. We found
that the reaction proceeded effectively at 50 C using 1.1 equiv of
1 and 0.05 equiv of NOBF4 in methylene chloride. Other organic
solvents were tested (e.g., acetonitrile, chloroform), but no
improvements in terms of yields and reaction time were observed.
The reaction was also subjected to microwave irradiation
instead of thermal activation. In this case, an overall 50% reduction
of the reaction time was possible.
These optimized conditions were applied on a variety of glycals
such as D-galactal, D-arabinal, L-arabinal and L-rhamnal. (Scheme 3)
and the corresponding Ferrier sulfamidoglycosylation products 3
were obtained in moderate to fairly good yields. In all cases, a mix-
ture of non-separable a- and b-anomers was obtained, with the a-
anomer being predominant in all cases (Table 1), as it was
observed also in the case of sulfonamidoglycosylation reactions
reported by Colinas and Bravo.5
Removal of the silyl protecting groups from compound 3 was
initially performed by standard methods using either tetra-n-butyl
ammonium fluoride (TBAF)8, or Selectfluor™9 and led to low yields
(20%) of the corresponding compound 4. Ultimately deprotection
of the silyl ether was carried out using HF–pyridine complex andO
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Scheme 3. Synthesis of compound 5 viacompound 4 were obtained in 85% yields.10 Final cleavage of the
acetyl group was done by using a methanolic solution of ammonia,
to afford quantitatively compound 5.
The structure of compounds 1, 3, 4 and 5, as well as the ratio of
a/b anomers were unambiguously confirmed using 1H, 13C, 2D
COSY pulseprog COSYGPQF (with gradient quadrature mode; time
domain size, TD = 2 k; relaxation delay, d1 = 1.5 s and scan num-
ber = 1), HMQC experiments.
Stereochemical assignment of the major diastereoisomer was
verified by NOESY pulseprog NOESYGPPHPP experiments (time
domain size, TD = 2 k; the mixing time d8 = 0.7 s; the relaxation
delay d1 = 1.5 s and scans number = 16), observing a NOE interac-
tion between H1 and H5 for the b-anomers (absent for the a
anomers).
At this point, we can provide two plausible mechanisms for the
sulfamidoglycosylation reaction of glycals, inspired by previous
work reported by Ansari et al.11 and Toshima et al.12 These mech-
anisms are depicted in Scheme 4 and illustrated in the case of the
peracetylated glucal 2a. In the first step of these mechanism one
electron coming or from the ring oxygen (pathway A) or from
the oxygen of the acetate group located on position 3 (pathway
B) could be accepted by the nitrosonium cation to give an acetate
radical (which in turn could accept an electron from NO to give
the acetate anion). Then the delocalized carbocation could under-
gone nucleophilic displacement reaction by the N-(O-tert-butyldi-
phenylsilyl)hydroxysulfamide 1 with allylic rearrangement
leading to the 2,3-unsaturated glycoside 3a as a mixture of a and
b anomers, a anomer being predominant.O
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Scheme 4. Proposed mechanisms for the sulfamidoglycosylation reaction/example of Glucal.
Table 2
Inhibitory activity of compounds 4a–4e and 5a–5e against the four CA isoforms: hCA I, II, IX and XII determined by a Stopped-Flow, CO2 Hydration Assay Method.13 Selectivity
ratios for the inhibition of the tumor-associated (CA IX and XII) over the cytosolic (CA II) isozyme are also reported
KI
a (nM) Selectivity ratio
hCA Ib hCA IIb hCA IXc hCA XIIc KI hCA II/KI hCA IX KI hCA II/KI hCA XII
AAZ 250 12 25 5.6 0.48 2.14
4a 813 94 90 76 1.04 1.23
4b 752 86 79 207 1.08 0.41
4c >10,000 >10,000 54 86 >185 >116
4d >10,000 >10,000 44 81 >227 >123
4e >10,000 94 47 93 2 1.01
5a >10,000 91 9 93 10.11 0.97
5b 917 >10,000 44 68 >227 >147
5c 927 >10,000 8 88 >1250 >113
5d >10,000 85 9 415 9.44 0.20
5e >10,000 >10,000 8 87 >1250 >114
a Errors in the range of ±5–10% of the reported value from three different determinations.
b Full length, cytosolic isoform.
c Catalytic domain, recombinant enzyme.
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The compounds reported here were investigated for the inhibi-
tion of four human (h) CA isoforms, involved in crucial physiologic
processes in mammals, the cytosolic, widespread hCA I and II, as
well as the tumor associated, transmembrane isoforms hCA IX
and XII. Inhibition data with compounds 4 and 5, as well as the sul-
fonamide in clinical use acetazolamide (as standard compound)
are reported in Table 2.
It may be observed that the slow cytosolic isoforms (hCA I) was
poorly or not at all inhibited by the compounds reported here. Just
4a, 4b, and 5b, 5c showed inhibition constants around 1000 nM,
whereas all other derivatives were not inhibitory against hCA I
up to 10 lM. hCA II showed a very unusual inhibition profile with
the new derivatives. In fact two peracetylated compounds (4c and
4d) and three deacetylated ones (5b, 5c and 5e) were not inhibi-
tory up to concentrations of 10 lM, whereas the remaining ones
showed medium potency inhibitory action, with KIs in the range
of 85–94 nM. Thus, in this case the nature of the glycal strongly
influences activity but in manner difficult to rationalize consider-
ing both the acetylated as well as the deacetylated series.
The tumor associated hCA IX on the other hand was effectively
inhibited by all the new compounds, with the acetylated deriva-
tives 4 being slightly less effective (KIs in the range of 44–90 nM)
than the deacetylated ones, 5, which had KIs in the range of 8–
44 nM. Generally the nature of the glycal was not very important
for the inhibitory power except galactal which led to a derivative
around one order of magnitude less potent compared to the other
sugar derivatives investigated here. hCA XII was moderately inhib-
ited by both compounds 4 and 5 reported here, with KIs in therange of 68–415 nM, with two compounds in each series (4b and
5d, respectively) showing the weakest inhibition (KIs of 207 and
415 nM, respectively) whereas the remaining ones showed a quite
compact behavior of medium potency inhibitor (KIs in the range of
68–93 nM).
Some of the new compounds reported here, such as 4c, 4d, 5b,
5c and 5e showed profiles of significant tumor-associated CAs
selective inhibitors, with selectivity ratios of >100 for inhibiting
hCA IX/XII over hCA I/II.
4. Conclusion
In conclusion, our methodology allowed the preparation of
hydroxysulfamide glycosides from glycals in good yields and with
a good alpha stereoselectivity. We have used an effective sulfami-
doglycosylation method using NOBF4 as a catalyst in dichloro-
methane. Studies on the inhibitory activity against the two
cytosolic CA isoforms: hCA I, II, and the two tumor associated,
membrane isoforms hCA IX and XII demonstrated the importance
of the sugar scaffold in the design of powerful and selective hCA
IX/hCA XII inhibitors with potential in antitumor therapy, although
the structure–activity relationship in this small series of inhibitors
is not at all straightforward.
5. Experimental section
5.1. General methods
Microwaves synthesis was carried out on CEM Discover Micro-
waves of CEM Corporation. The thin layer chromatographies (TLC)
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tions were monitored by TLC by using alumina plates coated with
silica gel and visualized either by using UV light or by charring
with of 10% sulfuric acid in ethanol solution. Column chromatogra-
phy was performed on silica gel 60 Å, particle size: 35–70 mesh. 1H
and 13C NMR spectra were recorded on Brucker-400 instrument
using the residual solvent signals as an internal reference. High-
resolution mass spectra (HRMS) were obtained from an ESI-TOF-
MS spectrometer (SYNAPT G2-S of Waters).
5.2. Microwave irradiation experiments
All microwave experiments were performed with CEM Discover
Synthesizer possessing (Sp). On this device, the temperature is con-
trolled via an optical fiber directly inside the reactor, providing
greater accuracy in the measurements. Experiments were carried
out in standard microwaves process vials 10 ml capacity (filled
with 7 ml max). The specifications used are pressure: 17 bars;
power: 150–200W; temperature: 50 C and power max: off.
5.3. Synthesis
5.3.1. N-(O-tert-Butyldiphenylsilyl)hydroxysulfamide (1)
Triethylamine (5 mL, 37 mmol) was added dropwise to a sus-
pension of hydroxylamine hydrochloride (1 g, 14.4 mmol) in anhy-
drous CH2Cl2 (20 mL) under N2 at 0 C. The mixture was stirred at
room temperature for 2 h. then cooled to 0 C. A solution of tert-
butyldiphenylsilyl chloride TBDPSCl (1.80 g, 12 mmol) in anhy-
drous CH2Cl2 (10 mL) was then slowly added at 0 C. The reaction
mixture was stirred at room temperature for 20 h. In a separate
flask, tert-butanol (1.14 mL, 12 mmol) was added dropwise to a
solution of chlorosulfonylisocyanate (1.02 mL, 12 mmol) in anhy-
drous CH2Cl2 (30 mL) under N2 at 0 C and stirred at 0 C for
40 min to give the tert-butoxycarbamoylsulfamoyl chloride. Trieth-
ylamine (5 mL, 37 mmol) was added to the solution of protected
hydroxylamine at 0 C and the solution containing the tert-but-
oxycarbamoylsulfamoyl chloride was added dropwise via a syringe.
The reactionmixturewas warmed to rt and stirred for 18 h. The sol-
vent was removed under reduced pressure. The residue was dis-
solved in EtOAc (100 mL) and washed with water (10 mL), 0.1 M
HCl (3  10 mL), satd NaHCO3 (3  10 mL), brine (15 mL). The
organic layer was finally dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The residue obtained was
then dissolved and stirred at 0 C in a solution of 10% TFA–CH2Cl2.
The reaction was monitored by TLC until the complete disappear-
ance of starting material. The solvent was removed under reduced
pressure to give the expected compound 1 in 78% yield.
Mp = 110 C; Rf = 0.30 (100% CH2Cl2); 1H NMR (400 MHz,
DMSO-d6) d 8.91 (s, 1H, NH), 7.70–7.79 (m, 4H, 4 CHortho), 7.43–
7.48 (m, 2H, 2 CHpara), 7.36–7.43 (m, 4H, 4 CHmeta), 6.95 (s,
2H, NH2), 1.07 (s, 9H, C(CH3)3). 13C NMR (101 MHz, DMSO-d6) d
135.5 (CHortho), 132.4 (CSi), 129.7 (CHpara), 127.4 (CHmeta), 26.8
(C(CH3)3), 19.1 (C(CH3)3). MS ESI m/z 351.15 [M+H]+.
5.3.2. General procedure for the synthesis of compound 3
To a solution of peracetylated glycal (1 mmol) and N-(O-tert-
butyldiphenylsilyl)hydroxysulfamide (1.1 mmol, 1.1 equiv) in
5 ml of dry CH2Cl2 was added NOBF4 (0.05 mmol, 0.05 equiv).
The mixture was then, or stirred under reflux (50 C) or stirred
under microwaves irradiations until completion of the reaction.
The reaction mixture was concentrated under reduced pressure
and the crude product was purified on silica gel using diethyl ether
and pentane as eluent (3a, 3b and 3e: Et2O/pentane 5:5; 3c and 3d
Et2O/pentane 6:4). Compound 3 are obtained as a mixture of a/b
isomers.5.3.2.1. Compound 3a. We introduced 0.272 g of 2a and we
obtained 0.383 g (yield D: 68%) and 0.394 g (MW: 70%). HRMS
calcd for C26H35N2O8SSi [M+H]+: 563.1883, found 563.1880
(0.3 mDa).
5.3.2.1.1. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-a-D-erythro-hex-2-
eno-pyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3a, anomer
a, 60%). 1H NMR (400 MHz, DMSO-d6) d 9.25 (s, 1H, NHOSi), 9.01
(d, 1H, J = 8.6 Hz, NHCH), 7.74–7.66 (m, 4H, 4 CHortho), 7.50–7.44
(m, 2H, 2 CHpara), 7.43–7.38 (m, 4H, 4 CHmeta), 5.90 (td, J = 10.2,
1.6 Hz, 1H, H-3), 5.82 (ddd, J = 10.2, 2.9, 2.1 Hz, 1H, H-2), 5.37 (ddd,
J = 8.6, 2.9, 1.6 Hz 1H, H-1), 5.20–5.16 (m, 1H, H-4), 4.15 (dd,
J = 11.6, 2.5 Hz, 1H, H-6a), 4.11–4.09 (m, 1H, H-5), 4.03 (dd,
J = 11.6, 4.3 Hz, 1H, H-6b), 2.06 (s, 3H, CH3COO), 1.98 (s, 3H,
CH3COO), 1.06 (s, 9H, 3 CH3). 13C NMR (101 MHz, DMSO-d6) d
169.9 (C@O), 169.6 (C@O), 135.5 (CHortho), 131.9 (CSi), 130.2
(CHpara), 128.4 (C-3), 127.6 (C-2), 127.3 (CHmeta), 76.2 (C-1), 66.8
(C-5), 64.1 (C-4), 62.3 (C-6), 26.61 (C(CH3)3), 20.59 (CH3COO),
20.29 (CH3COO), 18.93 (C(CH3)3).
5.3.2.1.2. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-b-D-threo-hex-2-eno-
pyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3a, anomer b,
40%). 1H NMR (400 MHz, DMSO-d6) d 9.18 (s, 1H, NHOSi), 8.88
(d, J = 8.6 Hz, 1H, NHCH), 7.74–7.66 (m, 4H, 4 CHortho), 7.50–
7.44 (m, 2H, 2 CHpara), 7.43–7.38 (m, 4H, 4 CHmeta), 5.87 (td,
J = 10.2, 1.6 Hz, 1H, H-3), 5.86 (td, J = 10.2, 1.3 Hz, 1H, H-2), 5.44–
5.39 (m, 1H, H-1), 5.24–5.20 (m, 1H, H-4), 4.15 (dd, J = 11.6,
2.5 Hz, 1H, H-6a), 4.05 (dd, J = 11.6, 4.3 Hz, 1H, H-6b), 3.86 (ddd,
J = 8.25, 4.74, 3.24 Hz, 1H, H-5), 2.04 (s, 3H, CH3COO), 1.97 (s, 3H,
CH3COO), 1.07 (s, 9H, 3 CH3). 13C NMR (101 MHz, DMSO-d6) d
169.8 (C@O), 169.6 (C@O), 135.5 (CHortho), 132.0 (CSi), 130.2
(CHpara), 129.8 (C-3), 127.8 (C-2), 127.3 (CHmeta), 78.8 (C-1), 73.2
(C-5), 63.9 (C-4), 62.6 (C-6), 26.61 (C(CH3)3), 20.59 (CH3COO),
20.31 (CH3COO), 18.87 (C(CH3)3).
5.3.2.2. Compound 3b. We introduced 0.272 g of 2b and we
obtained 0.394 g (yield D: 70%) and 0.394 g (MW: 70%). HRMS
calcd for C26H35N2O8SSi [M+H]+: 563.1883, found 563.1880
(0.3 mDa).
5.3.2.2.1. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-a-D-threo-hex-2-eno-
pyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3b, anomer a,
75%). 1H NMR (400 MHz, DMSO-d6) d 9.29 (s, 1H, NHOSi), 8.90
(d, J = 9.0 Hz, 1H, NHCH), 7.75–7.65 (m, 4H, 4 CHortho), 7.50–
7.44 (m, 2H, 2 CHpara), 7.44–7.37 (m, 4H, 4 CHméta), 6.06 (ddd,
J = 9.9, 5.4, 1.4 Hz, 1H, H-3), 6.02 (dd, J = 9.9, 3.2 Hz, 1H, H-2),
5.39 (ddd, J = 9.0, 3.0, 1.3 Hz, 1H, H-1), 4.96 (dd, 1H, H-4), 4.40
(dd, J = 6.5, 2.5 Hz, 1H, H-5), 4.14 (dd, J = 11.2, 6.5 Hz, 1H, H-6a),
4.00 (dd, J = 11.2, 6.5 Hz, 1H, H-6b), 2.01 (s, 3H, CH3COO), 1.93 (s,
3H, CH3COO), 1.07 (s, 9H, 3 CH3). 13C NMR (101 MHz, DMSO-d6)
d 170.2 (C@O), 170.1 (C@O), 135.9 (CHortho), 132.3 (CSi), 130.8 (C-
2), 130.2 (CHpara), 127.8 (CHmeta), 124.9 (C-3), 76.3 (C-1), 67.1 (C-
5), 62.2 (C-4), 62.0 (C-6), 27.03 (C(CH3)3), 20.7 (2 CH3COO), 19.4
(C(CH3)3).
5.3.2.2.2. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-b-D-erythro-hex-2-
eno-pyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3b, anomer
b, 25%). 1H NMR (400 MHz, DMSO-d6) d 9.14 (s, 1H, NHOSi),
9.00 (d, J = 9.4 Hz, 1H, NHCH), 7.75–7.65 (m, 4H, 4 CHortho),
7.50–7.44 (m, 2H, 4 CHpara), 7.44–7.37 (m, 4H, 4 CHmeta),
6.04 (ddd, J = 10.0, 5.0, 1.8, 1H, H-3), 5.99 (br d, J = 10.0 Hz, 1H,
H-2), 5.31 (d, J = 8.2 Hz, 1H, H-1), 5.05 (td, J = 5.0, 1.8 Hz,
1H, H-4), 4.09–4.11 (m, 2H, H-6a, H-6b), 4.03 (dt, J = 6.2, 2.4 Hz,
1H, H-5), 2.02 (s, 3H, CH3COO), 1.97 (s, 3H, CH3COO), 1.07 (s,
9H, 3 CH3). 13C NMR (101 MHz, DMSO-d6) d 170.4 (C@O),
170.3 (C@O), 135.9 (CHortho), 132.3 (CSi), 130.8 (C-2), 130.3
(CHpara), 127.8 (CHmeta), 124.9 (C-3), 79.4 (C-1), 72.3 (C-5), 63.0
(C-4), 62.5 (C-6), 26.99 (C(CH3)3), 20.81 (CH3COO), 20.76 (CH3-
COO), 19.34 (C(CH3)3).
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obtained 0.431 g (yield D: 88%) and 0.441 g (MW: 90%). HRMS
calcd for C23H31N2O6SSi [M+H]+: 491.1672, found 491.1675
(0.3 mDa).
5.3.2.3.1. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-a-D-erythro-
pent-2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3c,
anomer a, 60%). 1H NMR (400 MHz, DMSO-d6) d 9.13 (s, 1H,
NHOSi), 8.86 (d, J = 9.0 Hz, 1H, NHCH), 7.74–7.67 (m, 4H, 4
CHortho), 7.50–7.44 (m, 2H, 2 CHpara), 7.44–7.37 (m, 4H, 4
CHmeta), 6.04 (tdd, J = 9.9, 4.9, 1.3 Hz, 1H, H-3), 5.99–5.96 (m, 1H,
H-2), 5.35–5.31 (m, 1H, H-1), 4.90–4.84 (m, 1H, H-4), 4.18 (dd,
J = 13.1, 1.3 Hz, 1H, H-5a), 3.74 (dd, J = 13.1, 1.3 Hz, 1H, H-5b),
2.03 (s, 3H, CH3COO), 1.07 (s, 9H, 3 CH3). 13C NMR (101 MHz,
DMSO-d6) d 170.2 (C@O), 135.9 (CHortho), 132.3 (CSi), 130.9 (C-2),
130.2 (CHpara), 127.79 (CHmeta), 125.1 (C-3), 75.5 (C-1), 63.2 (C-4),
61.8 (C-5), 26.95 (C(CH3)3), 21.04 (CH3COO), 19.3 (C(CH3)3).
5.3.2.3.2. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-b-D-threo-pent-
2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3c, anomer
b, 40%). 1H NMR (400 MHz, DMSO-d6) d 9.15 (s, 1H, NHOSi), 8.96
(d, J = 9.0 Hz, 1H, NHCH), 7.74–7.67 (m, 4H, 4 CHortho), 7.50–7.44
(m, 2H, 2 CHpara), 7.44–7.37 (m, 4H, 4 CHmeta), 6.01–5.99 (m,
1H, H-3), 5.88 (ddd, J = 10.1, 2.2, 1.3 Hz, 1H, H-2), 5.26 (dd, J = 9.0,
2.0 Hz, 1H, H-1), 5.10–5.04 (m, 1H, H-4), 3.81 (dd, J = 11.8, 4.9 Hz,
1H, H-5a), 3.80 (dd, J = 11.8, 5.8 Hz, 1H, H-5b), 2.03 (s, 3H, CH3COO),
1.07 (s, 9H, 3 CH3). 13C NMR (101MHz, DMSO-d6) d 170.3 (C@O),
135.9 (CHortho) 132.3 (CSi), 130.6 (C-2), 130.2 (CHpara), 127.8 (C-3),
127.8 (CHmeta), 77.2 (C-1), 64.1 (C-4), 62.2 (C-5), 26.98 (C(CH3)3),
21.0 (CH3COO), 19.3 (C(CH3)3).
5.3.2.4. Compound 3d. We introduced 0.200 g of 2d and we
obtained 0.421 g (yield D: 86%) and 0.441 g (MW: 90%). HRMS
calcd for C23H31N2O6SSi [M+H] +: 491.1672, found 491.1672
(0.0 mDa).
5.3.2.4.1. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-a-L-erythro-
pent-2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3d,
anomer a, 60%). 1H NMR (400 MHz, DMSO-d6) d 9.13 (s, 1H,
NHOSi), 8.86 (d, J = 9.0 Hz, 1H, NHCH), 7.75–7.67 (m, 4H, 4
CHortho), 7.50–7.44 (m, 2H, 2 CHpara), 7.44–7.38 (m, 4H, 4
CHmeta), 6.04 (tdd, J = 10.1, 4.9, 1.4 Hz, 1H, H-3), 6.02–5.99 (m,
1H, H-2), 5.33 (dd, J = 9.0, 1.8 Hz, 1H, H-1), 4.89–4.84 (m, 1H, H-
4), 4.18 (dd, J = 13.2, 2.9 Hz, 1H, H-5a), 3.74 (dd, J = 13.2, 1.4 Hz,
1H, H-5b), 2.03 (s, 3H, CH3COO), 1.07 (s, 9H, 3 CH3). 13C NMR
(101 MHz, DMSO-d6) d 170.3 (C@O), 135.87 (CHortho), 132.26
(CSi), 130.9 (C-2), 130.2 (CHpara), 127.80 (CHmeta), 125.1 (C-3),
75.5 (C-1), 63.2 (C-4), 61.8 (C-5), 26.96 (C(CH3)3), 21.05 (CH3COO),
19.30 (C(CH3)3).
5.3.2.4.2. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-b-L-thréo-pent-
2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3d, anomer
b, 40%). 1H NMR (400 MHz, DMSO-d6) d 9.15 (s, 1H, NHOSi), 8.95
(d, J = 9.0 Hz, 1H, NHCH), 7.75–7.67 ((m, 4H, 4 CHortho), 7.50–7.44
(m, 2H, 2 CHpara), 7.44–7.38 (m, 4H, 4 CHmeta), 5.99–5.97 (m,
1H, H-3), 5.90 (ddd, J = 10.1, 2.1, 1.3 Hz, 1H, H-2), 5.26 (dd, J = 9.0,
1.9 Hz, 1H, H-1), 5.12–5.03 (m, 1H, H-4), 3.82 (dd, J = 11.7, 6.0 Hz,
1H, H-5a), 3.79 (dd, J = 11.7, 4.7 Hz, 1H, H-5b), 2.03 (s, 2H), 2.03 (s,
3H, CH3COO), 1.08 (s, 9H, 3 CH3). 13C NMR (101MHz, DMSO-d6)
d 170.2 (C@O), 135.85 (CHortho), 132.3 (CSi), 130.6 (C-2), 130.1
(CHpara), 127.82 (C-3), 127.80 (CHmeta), 77.2 (C-1), 64.1 (C-4), 62.2
(C-5), 26.98 (C(CH3)3), 21.00 (CH3COO), 19.30 (C(CH3)3).
5.3.2.5. Compound 3e. We introduced 0.214 g of 2e and we
obtained 0.444 g (yield D: 88%) and 0.454 g (MW: 90%). HRMS
calcd for C24H33N2O6SSi [M+H]+: 505.1829 found 505.1826
(0.3 mDa).
5.3.2.5.1. N-[1-(4-O-Acetyl-6-anhydro-2,3-dideoxy-a-L-threo-hex-
2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3e, anomer
a, 84%). 1H NMR (400 MHz, DMSO-d6) d 9.16 (s, 1H, NHOSi), 8.78(d, J = 9.2 Hz, 1H, NHCH), 7.74–7.68 (m, 4H, 4 CHortho), 7.50–7.44
(m, 2H, 2 CHpara), 7.44–7.37 (m, 4H, 4 CHmeta), 5.84–5.80 (m, 2H,
H-2, H-3), 5.34 (br s, 1H, H-1), 4.90–4.88 (m, 1H, H-4), 3.92 (d,
J = 6.2 Hz, 1H, H-5), 2.07 (s, 3H, CH3), 1.08 (s, 9H, 3 CH3), 1.07
(s, 3H, CH3COO). 13C NMR (101 MHz, DMSO-d6) d 170.0 (C@O),
135.6 (CHortho), 132.1 (CSi), 130.3 (C-2), 129.9 (CHpara), 128.9 (C-
3), 127.5 (CHmeta), 78.8 (C-1), 71.7 (C-5), 69.4 (C-4), 26.8
(C(CH3)3), 20.8 (CH3COO), 19.1 (C(CH3)3), 18.3 (CH3).
5.3.2.5.2. N-[1-(4-O-Acetyl-6-anhydro-2,3-dideoxy-b-L-erythro-
hex-2-enopyranosyl)]-N-(O-tert-butyldiphenylsilyl)sulfamide (3e, ano-
mer b, 16%). 1H NMR (400 MHz, DMSO-d6) d 9.10 (s, 1H, NHOSi),
8.97 (d, J = 8.9 Hz, 1H, NHCH), 7.74–7.68 (m, 4H, 4 CHortho), 7.50–
7.44 (m, 2H, 2 CHpara), 7.44–7.37 (m, 4H, 4 CHmeta), 5.90–5.85
(m, 2H, H-2, H-3), 5.32 (br s, 1H, H-1), 4.88–4.85 (m, 1H, H-4),
3.94 (d, J = 6.2 Hz, 1H, H-5), 2.07 (s, 3H, CH3), 1.08 (s, 9H, 3 CH3),
1.07 (s, 3H, CH3COO). 13C NMR (101 MHz, DMSO-d6) d 170.0
(C@O), 135.6 (CHortho), 132.1 (CSi), 130.3 (C-2), 129.9 (CHpara),
128.9 (C-3), 127.5 (CHmeta), 76.2 (C-1), 69.6 (C-4), 65.0 (C-5), 26.8
(C(CH3)3), 20.8 (CH3COO), 19.1 (C(CH3)3), 18.3 (CH3).
5.3.3. General procedure for the synthesis of compound 4
To a solution of compound 3 (0.63 mmol) in 7 ml of CH3CN was
added 1.7 equiv of HFpyr complex (70%) at room temperature for
3 h. The reaction was then quenched by addition of Et3N (5 ml) and
the mixture was concentrated under vacuum. The crude product
was then purified by silica gel column chromatography using
diethyl ether and pentane as eluent (4a, 4b and 4e: Et2O/pentane
7:3; 4c and 4d Et2O/pentane 8:2). The expected compound 4 (mix-
ture a/b) are obtained in 85% yield.
5.3.3.1. Compound 4a. We introduced 0.353 g of 3a and we
obtained 0.173 g (yield: 85%). HRMS calcd for C10H17N2O8S
[M+H]+: 325.0706, found 325.0703 (0.3 mDa).
5.3.3.1.1. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-a-D-erythro-hex-2-
eno-pyranosyl)]-N-hydroxysulfamide (4a, anomer a, 77%). 1H
NMR (400 MHz, DMSO-d6) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H,
NHCH), 5.87 (td, J = 10.5, 1.8 Hz, 1H, H-3), 5.79 (ddd, J = 10.5, 3.2,
2.5 Hz, 1H, H-2), 5.24 (ddd, J = 9.2, 2.9, 1.8 Hz, 1H, H-1), 5.12–
5.10 (m, 1H, H-4), 4.12 (dd, J = 12.0, 4.1 Hz, 1H, H-6a), 4.12–4.08
(m, 1H, NHOH), 4.08–4.05 (m, 1H, H-5), 4.03 (dd, J = 11.6, 4.3 Hz,
1H, H-6b), 2.05 (s, 3H, CH3COO), 2.02 (s, 3H, CH3COO). 13C NMR
(101 MHz, DMSO-d6) d 170.0 (C@O), 169.8 (C@O), 130.4 (s, 1H, C-
3), 127.0 (C-2), 87.5 (C-1), 65.8 (C-5), 64.8 (C-4), 62.8 (C-6), 20.4
(CH3COO).
5.3.3.1.2. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-b-D-threo-hex-2-eno-
pyranosyl)]-N-hydroxysulfamide (4a, anomer b, 23%). 1H NMR
(400 MHz, DMSO-d6): d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH),
5.84 (td, J = 10.5, 1.6 Hz, 1H, H-3), 5.79 (td, J = 10.5, 1.3 Hz, 1H,
H-2), 5.33–5.28 (m, 1H, H-1), 5.14–5.12 (m, 1H, H-4), 4.12–4.08
(m, 3H, NHOH, H-6a, H-6b), 3.89 (ddd, J = 8.2, 4.7, 3.2 Hz, 1H,
H-5), 2.04 (s, 3H, CH3COO), 2.03 (s, 3H, CH3COO). 13C NMR
(101 MHz, DMSO-d6) d 170.0 (C@O), 169.8 (C@O), 132.9 (C-3),
126.0 (C-2), 90.3 (C-1), 72.1 (C-5), 64.3 (C-4), 62.9 (C-6), 20.6
(CH3COO).
5.3.3.2. Compound 4b. We introduced 0.357 g of 3b and we
obtained 0.175 g (yield: 85%). HRMS calcd for C10H17N2O8S
[M+H]+: 325.0706, found 325.0703 (0.3 mDa).
5.3.3.2.1. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-a-D-threo-hex-2-eno-
pyranosyl)]-N-hydroxysulfamide (4b, anomer a, 77%). 1H NMR
(400 MHz, DMSO-d6) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH),
6.07 (ddd, J = 9.9, 5.3, 1.4 Hz, 1H, H-3), 6.02 (dd, J = 9.9, 3.3 Hz,
1H, H-2), 5.42–5.38 (m, 1H, H-1), 4.96 (dd, J = 5.2, 2.5 Hz, 1H, H-
4), 4.40 (dd, J = 6.5, 2.5 Hz, 1H, H-5), 4.13–4.10 (m, 1H, NHOH),
4.09 (dd, J = 12.0, 4.1 Hz, 1H, H-6a), 4.06 (dd, J = 11.2, 6.5 Hz, 1H,
H-6b), 1.95 (s, 6H, 2 CH3COO). 13C NMR (101 MHz, DMSO-d6) d
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(C-4), 62.7 (C-6), 20.4 (2 CH3COO).
5.3.3.2.2. N-[1-(4,6-Di-O-acetyl-2,3-dideoxy-b-D-erythro-hex-2-
eno-pyranosyl)]-N-hydroxysulfamide (4b, anomer b, 23%). 1H
NMR (400 MHz, DMSO-d6) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H,
NHCH), 6.05 (ddd, J = 10.1, 5.1, 1.6 Hz, 1H, H-3), 6.00 (br d,
J = 10.5 Hz, 1H, H-2), 5.34 (dd, J = 9.0, 4.7 Hz, 1H, H-1), 4.96 (dd,
J = 5.0, 1.8 Hz, 1H, H-4), 4.13–4.10 (m, 3H, NHOH, H-6a, H-6b),
4.08 (dt, J = 6.2, 2.4 Hz, 1H, H-5), 2.00 (s, 6H, 2 CH3COO). 13C
NMR (101 MHz, DMSO-d6) d 170.0 (C@O), 133.1 (C-2), 126.1 (C-
3), 90.3 (C-1), 72.27 (C-5), 64.9 (C-4), 64.4 (C-6), 20.6 (2 CH3COO).
5.3.3.3. Compound 4c. We introduced 0.309 g of 3c and we
obtained 0.135 g (yield: 85%). HRMS calcd for C7H13N2O6S
[M+H]+: 253.0494, found 253.0492 (0.2 mDa).
5.3.3.3.1. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-a-D-erythro-
pent-2-enopyranosyl)]-N-hydroxysulfamide (4c, anomer a, 77%). 1H
NMR (400 MHz, DMSO-d6) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH),
6.07–6.02 (m, 1H, H-3), 5.99–5.96 (m, 1H, H-2), 5.36–5.33 (m, 1H, H-
1), 4.90–4.84 (m, 1H, H-4), 4.22–4.13 (m, 2H, H-5a, H-5b), 3.85–3.69
(m, 1H, NHOH), 2.03 (s, 3H, CH3COO). 13C NMR (101 MHz, DMSO-d6)
d 170.2 (C@O), 130.9 (C-2), 125.1 (C-3), 87.6 (C-1), 63.2 (C-4), 61.8
(C-5), 21.04 (CH3COO).
5.3.3.3.2. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-b-D-threo-pent-
2-enopyranosyl)]-N-hydroxysulfamide (4c, anomer b, 23%). 1H NMR
(400 MHz, DMSO-d6) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH),
6.07–6.02 (m, 1H, H-3), 5.88 (ddd, J = 10.1, 2.2, 1.3 Hz, 1H, H-2),
5.26 (dd, J = 9.0, 2.0 Hz, 1H, H-1), 4.90–4.84 (m, 1H, H-4), 3.85–
3.69 (m, 3H, H-5a, H-5b, NHOH), 2.03 (s, 3H, CH3COO). 13C NMR
(101MHz, DMSO-d6) d 170.3 (C@O), 130.6 (C-2), 127.8 (C-3), 90.5
(C-1), 64.1 (C-4), 62.2 (C-5), 21.0 (CH3COO).
5.3.3.4. Compound 4d. We introduced 0.311 g of 3d and we
obtained 0.136 g (yield: 85%). HRMS calcd for C7H13N2O6S
[M+H]+: 253.0494, found 253.0494 (0.0 mDa).
5.3.3.4.1. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-a-L-threo-pent-
2-enopyranosyl)]-N-hydroxysulfamide (4d, anomer a, 77%). 1H NMR
(400 MHz, DMSO-d6) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH), 6.08–
6.01 (m, 1H, H-3), 6.00–5.97 (m, 1H, H-2), 5.35 (dd, J = 9.0, 1.8 Hz,
1H, H-1), 4.89–4.84 (m, 1H, H-4), 4.22–4.13 (m, 2H, H-5a, H-5b),
3.84–3.70 (m, 1H, NHOH), 2.04 (s, 3H, CH3COO). 13C NMR
(101MHz, DMSO-d6) d 170.2 (C@O), 131.0 (C-2), 125.2 (C-3), 87.4
(C-1), 63.3 (C-4), 61.9 (C-5), 21.05 (CH3COO).
5.3.3.4.2. N-[1-(4-O-Acetyl-5-anhydro-2,3-dideoxy-b-L-erythro-
pent-2-enopyranosyl)]-N-hydroxysulfamide (4d, anomer b, 23%). 1H
NMR (400 MHz, DMSO-d6) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH),
6.08–6.01 (m, 1H, H-3), 6.00–5.97 (m, 1H, H-2), 5.27 (dd, J = 9.0,
2.0 Hz, 1H, H-1), 4.88–4.85 (m, 1H, H-4), 3.84–3.70 (m, 2H, H-5a,
H-5b, NHOH), 2.03 (s, 3H, CH3COO). 13C NMR (101MHz, DMSO-d6)
d 170.3 (C@O), 130.3 (C-2), 127.8 (C-3), 90.3 (C-1), 64.2 (C-4), 62.2
(C-5), 21.00 (CH3COO).
5.3.3.5. Compound 4e. We introduced 0.318 g of 3e and we
obtained 0.143 g (yield: 85%). HRMS calcd for C8H15N2O6S
[M+H]+: 267.0651, found 267.0654 (0.3 mDa).
5.3.3.5.1. N-[1-(4-O-Acetyl-6-anhydro-2,3-dideoxy-a-L-erythro-
hex-2-enopyranosyl)]-N-hydroxysulfamide (4e, anomer a, 77%). 1H
NMR (400 MHz, DMSO-d6) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H,
NHCH), 5.90–5.85 (m, 2H, H-2, H-3), 5.32 (br s, 1H, H-1), 4.88–
4.85 (m, 1H, H-4), 3.98–3.89 (m, 2H, H-5, NHOH), 2.07 (s, 3H,
CH3), 1.07 (s, 3H, CH3COO). 13C NMR (101 MHz, DMSO-d6) d
170.0 (C@O), 130.2 (C-2), 127.5 (C-3), 87.4 (C-1), 69.6 (C-4), 65.1
(C-5), 20.8 (CH3COO), 19.1 (CH3).
5.3.3.5.2. N-[1-(4-O-Acetyl-6-anhydro-2,3-dideoxy-b-L-threo-hex-
2-enopyranosyl)]-N-hydroxysulfamide (4e, anomer b, 23%). 1H
NMR (400 MHz, DMSO-d6) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H,NHCH), 5.84–5.80 (m, 2H, H-2, H-3), 5.34 (br s, 1H, H-1), 4.90–
4.88 (m, 1H, H-4), 3.98–3.89 (m, 2H, H-5, NHOH), 2.07 (s, 3H,
CH3), 1.07 (s, 3H, CH3COO). 13C NMR (101 MHz, DMSO-d6) d
170.0 (C@O), 130.2 (C-2), 127.5 (C-3), 90.3 (C-1), 69.6 (C-4), 65.1
(C-5), 20.8 (CH3COO), 19.1 (CH3).
5.3.4. General procedure for the synthesis of compound 5
Compound 4 (0.318 mmol) were dissolved in a 2.0 M NH3
methanolic solution (8 ml) at 0–5 C. The reaction was stirred at
4 C overnight, then concentrated under vacuum to give compound
5 (a and b anomers mixture) in quantitative yield.
5.3.4.1. Compound 5a. We introduced 0.103 g of 4a and we
obtained 0.076 g (yield: 100%). HRMS calcd for C6H13N2O6S
[M+H]+: 241.0494, found 241.0496 (0.2 mDa).
5.3.4.1.1. N-[1-(2,3-Dideoxy-a-D-erythro-hex-2-enopyranosyl)]-N-
hydroxysulfamide (5a, anomer a, 77%). 1H NMR (400 MHz, D2O) d
6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH), 5.90–5.88 (m, 1H, H-3),
5.85–5.83 (m, 1H, H-2), 5.29 (ddd, J = 9.4, 3.5, 1.7 Hz, 1H, H-1),
4.22 (dd, J = 8.8, 2.2 Hz, 1H, H-4), 3.89–3.87 (m, 4H, H-5, H-6a, H-
6b, NHOH), 3.70–3.65 (m, 2H, OH). 13C NMR (101 MHz, D2O) d
130.4 (C-3), 127.0 (C-2), 87.5 (C-1), 78.1 (C-5), 68.3 (C-4), 60.0
(C-6).
5.3.4.1.2. N-[1-(2,3-Dideoxy-b-D-threo-hex-2-eno-pyranosyl)]-N-
hydroxysulfamide (5a, anomer b, 23%). 1H NMR (400 MHz, D2O)
d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH), 5.90–5.88 (m, 1H, H-3),
5.85–5.83 (m, 1H, H-2), 5.32–5.26 (m, 1H, H-1), 4.24 (dd, J = 7.7,
1.5 Hz, 1H, H-4), 3.89–3.87 (m, 4H, H-5, H-6a, H-6b, NHOH),
3.70–3.65 (m, 2H, OH). 13C NMR (101 MHz, D2O) d 130.35 (C-3),
127.02 (C-2), 90.34 (C-1), 78.11 (C-5), 68.78 (C-4), 60.03 (C-6).
5.3.4.2. Compound 5b. We introduced 0.103 g of 4b and we
obtained 0.077 g (yield: 100%). HRMS calcd for C6H13N2O6S
[M+H]+: 241.0494, found 241.0496 (0.2 mDa).
5.3.4.2.1. N-[1-(2,3-Dideoxy-a-D-threo-hex-2-eno-pyranosyl)]-N-
hydroxysulfamide (5b, anomer a, 77%). 1H NMR (400 MHz, D2O)
d 6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH), 5.90–5.88 (m, 1H, H-3),
5.85–5.83 (m, 1H, H-2), 5.26–5.22 (m, 1H, H-1), 4.22 (dd, J = 6.0,
2.1 Hz, 1H, H-4) 3.93–3.88 (m, 4H, H-5, H-6a, H-6b, NHOH),
3.70–3.65 (m, 2H, OH). 13C NMR (101 MHz, D2O) d 130.2 (C-3),
127.8 (C-2), 88.3 (C-1), 78.0 (C-5), 68.2 (C-4), 60.1 (C-6).
5.3.4.2.2. N-[1-(2,3-Dideoxy-b-D-erythro-hex-2-eno-pyranosyl)]-
N-hydroxysulfamide (5b, anomer b, 23%). 1H NMR (400 MHz,
D2O) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH), 5.90–5.88 (m, 1H,
H-3), 5.85–5.83 (m, 1H, H-2), 5.33–5.28 (m, 1H, H-1), 4.24 (dd,
J = 6.2, 1.9 Hz, 1H, H-4), 3.93–3.88 (m, 4H, H-5, H-6a, H-6b, NHOH),
3.70–3.65 (m, 2H, OH). 13C NMR (101 MHz, D2O) d 130.2 (C-3),
127.8 (C-2), 91.0 (C-1), 78.0 (C-5), 68.8 (C-4), 60.1 (C-6).
5.3.4.3. Compound 5c. We introduced 0.080 g of 4c and we
obtained 0.067 g (yield: 100%). HRMS calcd for C5H11N2O5S
[M+H]+: 211.0389, found 211.0386 (0.3 mDa).
5.3.4.3.1. N-[1-(5-Anhydro-2,3-dideoxy-a-D-erythro-pent-2-eno-
pyranosyl)]-N-hydroxysulfamide (5c, anomer a, 77%). 1H NMR
(400 MHz, D2O) d 7.32 (s, 1H, NHOH), 7.09 (s, 1H, NHCH), 5.98–
5.96 (m, 1H, H-3), 5.96–5.94 (m, 1H, H-2), 5.47–5.45 (m, 1H, H-
1), 4.61–4.59 (m, 1H, H-4), 4.18–3.99 (m, 3H, H-5a, H-5b, NHOH),
3.55 (br s, 1H, NHOH). 13C NMR (101 MHz, D2O) d 130.8 (C-2),
127.6 (C-3), 88.0 (C-1), 64.0 (C-4), 63.3 (C-5).
5.3.4.3.2. N-[1-(5-Anhydro-2,3-dideoxy-b-D-threo-pent-2-enopyr-
anosyl)]-N-hydroxysulfamide (5c, anomer b, 23%). 1H NMR
(400 MHz, D2O) d 7.30 (s, 1H, NHOH), 7.08 (s, 1H, NHCH), 5.98–
5.96 (m, 1H, H-3), 5.96–5.94 (m, 1H, H-2), 5.44–5.43 (m, 1H, H-
1), 4.65–4.64 (m, 1H, H-4), 4.18–3.99 (m, 3H, H-5a, H-5b, NHOH),
3.55 (br s, 1H, NHOH). 13C NMR (101 MHz, D2O) d 130.8 (C-2),
127.6 (C-3), 92.0 (C-1), 64.0 (C-4), 63.3 (C-5).
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obtained 0.067 g (yield: 100%). HRMS calcd for C5H12N2O5S
[M+H]+: 211.0389, found 211.0388 (0.1 mDa).
5.3.4.4.1. N-[1-(5-Anhydro-2,3-dideoxy-a-L-threo-pent-2-eno-
pyranosyl)]-N-hydroxysulfamide (5d, anomer a, 77%). 1H NMR
(400 MHz, D2O) d 7.29 (s, 1H, NHOH), 6.99 (s, 1H, NHCH), 5.95–
5.90 (m, 1H, H-3), 5.89–5.85 (m, 1H, H-2), 5.38–5.35 (m, 1H, H-
1), 4.69–4.63 (m, 1H, H-4), 4.21–4.13 (m, 3H, H-5a, H-5b, NHOH),
3.86 (br s, 1H, NHOH). 13C NMR (101 MHz, D2O) d 130.52 (C-2),
127.64 (C-3), 87.16 (C-1), 66.09 (C-4), 63.42 (C-5).
5.3.4.4.2. N-[1-(5-Anhydro-2,3-dideoxy-b-L-erythro-pent-2-eno-
pyranosyl)]-N-hydroxysulfamide (5d, anomer b, 23%). 1H NMR
(400 MHz, D2O) d 7.26 (s, 1H, NHOH), 6.96 (s, 1H, NHCH), 5.95–
5.90 (m, 1H, H-3), 5.89–5.85 (m, 1H, H-2), 5.38–5.35 (m, 1H, H-
1), 4.63–451 (m, 1H, H-4), 4.21–4.13 (m, 3H, H-5a, H-5b, NHOH),
3.86 (br s, 1H, NHOH). 13C NMR (101 MHz, D2O) d 130.52 (C-2),
127.76 (C-3), 91.54 (C-1), 66.09 (C-4), 63.42 (C-5).
5.3.4.5. Compound 5e. We introduced 0.085 g of 4e and we
obtained 0.072 g (yield: 100%). HRMS calcd for C6H13N2O5S
[M+H]+: 225.0545, found 225.0543 (0.2 mDa).
5.3.4.5.1. N-[1-(6-Anhydro-2,3-dideoxy-a-L-threo-hex-2-eno-pyran-
osyl)]-N-hydroxysulfamide (5e, anomer a, 77%). 1H NMR (400MHz,
D2O) d 6.92 (s, 1H, NHOH), 6.69 (s, 1H, NHCH), 6.07 (m, 1H,
H-3), 6.02–5.98 (m, 1H, H-2), 5.41–5.39 (m, 1H, H-1), 4.45–4.40 (m,
1H, H-4), 3.98–3.89 (m, 2H, H-5, NHOH), 2.00 (br s, 3H, CH3). 13C
NMR (101 MHz, D2O) d 130.1 (C-2), 126.9 (C-3), 87.4 (C-1), 70.5
(C-4), 66.0 (C-5), 19.6 (CH3).
5.3.4.5.2. N-[1-(6-Anhydro-2,3-dideoxy-b-L-erythro-hex-2-eno-
pyranosyl)]-N-hydroxysulfamide (5e, anomer b, 23%). We intro-
duced 0.085 g of 4e and we obtained 0.072 g (yield: 100%). 1H
NMR (400 MHz, D2O) d 6.90 (s, 1H, NHOH), 6.68 (s, 1H, NHCH),
6.07 (m, 1H, H-3), 6.02–5.98 (m, 1H, H-2), 5.39–5.37 (m, 1H, H-
1), 4.39–4.37 (m, 1H, H-4), 3.97–3.86 (m, 2H, H-5, NHOH, OH),
2.00 (br s, 3H, CH3). 13C NMR (101 MHz, D2O) d 130.1 (C-2),
124.9 (C-3), 90.4 (C-1), 70.5 (C-4), 66.0 (C-5), 19.6 (CH3).
5.4. CA inhibition assays
CO2 hydrase assay: an Applied Photophysics stopped-flow
instrument has been used for assaying the CA-catalyzed CO2
hydration activity.13 Phenol red (at a concentration of 0.2 mM)
has been used as an indicator, working at the absorbance maxi-
mum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and
20 mM Na2SO4 (for maintaining constant the ionic strength), fol-
lowing the initial rates of the CA-catalyzed CO2 hydration reaction
for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to
17 mM for the determination of the kinetic parameters and inhibi-
tion constants. For each inhibitor, at least six traces of the initial 5–
10% of the reaction have been used for determining the initial
velocity. The uncatalyzed rates were determined in the same man-
ner and subtracted from the total observed rates. Stock solutions of
inhibitor (0.1 mM) were prepared in distilled–deionized water, and
dilutions up to 0.01 nM were done thereafter with distilled–deion-
ized water. Inhibitor and enzyme solutions were preincubated
together for 15 min at room temperature prior to assay, to allow
for the formation of the E–I complex. The inhibition constants were
obtained by nonlinear least squares methods using the
Cheng–Prusoff equation and represent the mean from at least threedifferent determinations. Errors were in the range of ±5–10% of the
reported KI values. CA isoforms were recombinant enzymes
obtained in house as reported earlier.14–16 The enzyme concentra-
tions in the assay system were: hCA I: 13.2 nM; hCA II: 8.4 nM;
hCA IX: 7.9 nM; hCA XII: 15.2 nM; hCA XIV: 10.7 nM.Acknowledgments
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